Evidence map›Paper›PMID 40401974›Full record

ArticleMicrobiology spectrum2025

Nitazoxanide and tizoxanide demonstrate high levels of

Keonte J Graves, John C Williamson, Jan Novak, Hemant K Tiwari, W Evan Secor, Christina A Muzny

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Innovative Z-Scheme Heterojunction Photocatalyst ZnBiGdOInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Keonte J GravesDivision of Infectious Diseases, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0002-8646-3801
John C WilliamsonDepartment of Internal Medicine, Section on Infectious Diseases, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Jan NovakDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Hemant K TiwariDepartment of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA.
W Evan SecorDivision of Parasitic Diseases and Malaria, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Christina A MuznyDivision of Infectious Diseases, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0002-4005-3858

Funding

Identification of Trichomonas vaginalis resistance targets to inform future drug developmentF31AI161785 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GRAVES, KEONTE J · 2022 to 2024
$77k
National Institute of Allergy and Infectious Diseases AI161785NIAID NIH HHS F31 AI161785
6 · The paper itself

Abstract

IMPORTANCE: Investigating drug resistance and alternative treatment options for

Indexed as

Antiprotozoal AgentsMetronidazoleThiazolesTrichomonas vaginalisDrug ResistanceFemaleHumansMicrobial Sensitivity TestsNitro CompoundsNitroimidazolesParasitic Sensitivity TestsTrichomonas InfectionsTrichomonas VaginitisAntiprotozoal AgentsMetronidazolenitazoxanideNitro CompoundsNitroimidazolessecnidazoleThiazolestizoxanide5-nitroimidazoledrug resistancenitazoxanidetizoxanideTrichomonas vaginalis

Identifiers

PMID40401974
PMCPMC12210956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.